Stay updated with breaking news from First Line Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PATIENTS IN SCOTLAND WITH AN ADVANCED FORM OF PROSTATE CANCER CAN NOW ACCESS LYNPARZA (OLAPARIB) WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE WITHOUT A BIOMARKER TEST
A survey of pediatric dermatologists revealed that topical corticosteroids are the most common first-line treatment for children with alopecia areata, regardless of age or hair loss severity.
Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).
Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.
Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.